Mar 11 |
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
|
Feb 15 |
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
|
Dec 20 |
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
|
Dec 7 |
Acelyrin Looks Interesting Before PsA Data In Q1
|
Nov 28 |
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
|
Nov 28 |
Biggest stock movers today: Micron, PDD Holdings, Carlyle Group, Zscaler and more
|
Nov 28 |
5 Things to Know Before Markets Open
|
Nov 27 |
Acelryin reports dose sequencing errors in Phase 2/3 study for izokibep
|
Nov 27 |
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
|
Nov 11 |
Acelyrin Inc. (SLRN) Q3 2023 Earnings Call Transcript
|